SCHEMBL49539

SCHEMBL49539

N[Si](c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
ALDH1A1 P00352 3/20 0.35
CYP3A4 P08684 2/20 0.33
CASP1 P29466 2/20 0.33
CASP7 P55210 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAOA P21397 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
DPP4 P27487 2/20 0.33
ADORA3 P0DMS8 2/20 0.33
RAB9A P51151 2/20 0.33
KDM4E B2RXH2 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
ALOX15 P16050 1/20 0.33
KCNN4 O15554 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3900193 0.79 TSHR (0.39) TSHRESR1ESR2ALDH1A1CYP3A4
SCHEMBL7877395 0.79 TSHR (0.47) TSHRESR1ESR2ALDH1A1CYP3A4
SCHEMBL843029 0.73 ESR1 (0.44) TSHRESR1ESR2ALDH1A1SMN1; SMN2
SCHEMBL6858049 0.73 ESR1 (0.44) TSHRESR1ESR2ALDH1A1CASP1
SCHEMBL242095 0.69 ALDH1A1 (0.40) TSHRESR1ESR2ALDH1A1SMN1; SMN2
SCHEMBL464991 0.69 ALDH1A1 (0.40) TSHRESR1ESR2ALDH1A1SMN1; SMN2
SCHEMBL8194001 0.69 ESR1 (0.41) TSHRESR1ESR2ALDH1A1CYP3A4
SCHEMBL3889075 0.67 CA4 (0.38) TSHRESR1ESR2ALDH1A1CASP1
SCHEMBL10280463 0.67 TP53 (0.38) ESR1ESR2ALDH1A1MAOARAB9A
SCHEMBL3886644 0.67 CA4 (0.38) TSHRESR1ESR2ALDH1A1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746922-A2 INTERLEUKIN-13 RECEPTOR SUBUNIT ALPHA-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF Exelixis, Inc. (US) 2026-05-27 EP claimed
EP-4747282-A1 ACTIVATABLE TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR (ROR) ANTIBODY-DRUG CONJUGATES AND USES THEREOF Exelixis, Inc. (US) 2026-05-27 EP claimed
EP-4747283-A1 TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR 1 (ROR1) ANTIBODY-DRUG CONJUGATES AND USES THEREOF Exelixis, Inc. (US) 2026-05-27 EP claimed
CN-113647198-B Polarizing plate NITTO DENKO CORP. (JP) 2026-05-26 CN claimed
CN-116194989-B System and method for hierarchical audio source separation MITSUBISHI ELECTRIC CORP. (JP) 2026-05-26 CN claimed
CN-122050840-A Prostate cancer multi-mode data analysis system based on cloud collaboration 南通大学附属医院 2026-05-15 CN claimed
US-20260099093-A1 PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR PRODUCING CURED RELIEF PATTERN USING SAME, AND METHOD FOR PRODUCING POLYIMIDE FILM USING SAME ASAHI KASEI KABUSHIKI KAISHA (JP) 2026-04-09 US claimed
WO-2026044352-A1 TWO-PARTNER SECRETION SYSTEM BINDING COMPOUNDS THE UNIVERSITY OF SYDNEY (AU) 2026-03-05 WO claimed
US-12510543-B2 Prostate antigen standards and uses thereof OPKO DIAGNOSTICS, LLC (US) 2025-12-30 US claimed
WO-2025228813-A1 METHOD OF STRATIFYING HAEMATURIA PATIENTS RANDOX LABORATORIES LTD (GB) 2025-11-06 WO claimed
EP-2074087-A2 SYNTHESIS OF PYRROLIDINE COMPOUNDS Wyeth (US) 2009-07-01 EP claimed
US-20080188545-A1 (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions ZEALAND PHARMA A/S (DK) 2008-08-07 US claimed
WO-2008079266-A2 SYNTHESIS OF PYRROLIDINE COMPOUNDS WYETH (US) 2008-07-03 WO claimed
EP-1881955-A1 BIS-AMINATION OF ARYL HALIDES Boehringer Ingelheim International GmbH (DE) 2008-01-30 EP claimed
WO-2006124283-A1 BIS-AMINATION OF ARYL HALIDES BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) 2006-11-23 WO claimed
US-20060258888-A1 Bis-Amination of Aryl Halides BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) 2006-11-16 US claimed
US-7129187-B2 Low-temperature plasma-enhanced chemical vapor deposition of silicon-nitrogen-containing films TOKYO ELECTRON LIMITED (JP) 2006-10-31 US claimed
WO-2006019438-A2 LOW-TEMPERATURE PLASMA-ENHANCED CHEMICAL VAPOR DEPOSITION OF SILICON-NITROGEN-CONTAINING FILMS TOKYO ELECTRON LIMITED (JP) 2006-02-23 WO claimed
US-20060014399-A1 Low-temperature plasma-enhanced chemical vapor deposition of silicon-nitrogen-containing films TOKYO ELECTRON LIMITED 2006-01-19 US claimed
US-6365643-B1 Photoinitiators for cationic curing TH. GOLDSCHMIDT AG (DE) 2002-04-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260099093-A1 PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR PRODUCING CURED RELIEF PATTERN USING SAME, AND METHOD FOR PRODUCING POLYIMIDE FILM USING SAME CD79B, ITGA1, PTK2 TSHR 2388/4885ESR1 1779/4885ESR2 1941/4885
US-20060258888-A1 Bis-Amination of Aryl Halides ABL1, AOC2, AADAC TSHR 926/4885ESR1 3593/4885ESR2 1995/4885
US-20080188545-A1 (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions GLS, COL2A1, MYOC TSHR 4384/4885ESR1 1567/4885ESR2 291/4885
US-12510543-B2 Prostate antigen standards and uses thereof KLK3, KLK4, KLK2 TSHR 4205/4885ESR1 722/4885ESR2 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.